Cardiac toxicity: old and new issues in anti-cancer drugs.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
M SerenoM González-Barón

Abstract

Although rare, cardiotoxicity is a significant complication of cancer treatment. The incidence and severity of cardiovascular side effects are dependent on the type of drugs used, dose and schedule employed, and age of patients, as well as the presence of coexisting cardiac diseases and previous mediastinal irradiation. Classically, anthracyclines are among one of the most active agents in oncology, but their use is often hampered by their cumulative dose-limiting cardiotoxicity. In the past decade, combination therapy with new drugs such as taxanes or anti- EGFR, and Her-2 therapy as a single agent have also resulted in unexpected cardiotoxicity. Cardiac damage can be secondary to an alteration of cardiac rhythm, changes in blood pressure and ischaemia, and can also alter the ability of the heart to contract and/or relax. The clinical spectrum of these toxicities can range from subclinical abnormalities to being catastrophic, life-threatening and sometimes fatal. Knowledge of this toxicity can aid clinicians to choose the optimal and least toxic regimen suitable for an individual patient. In this work we present an exhaustive review of the cardiovascular side effects associated to new anticancer drugs, from new formulations of...Continue Reading

References

Nov 1, 1979·Annals of Internal Medicine·D D Von HoffF M Muggia
Nov 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M de ForniP Soulié
Nov 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D NielsenM Hansen
Sep 24, 1998·The New England Journal of Medicine·P K Singal, N Iliskovic
Nov 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M RybergP Dombernowsky
Dec 3, 1999·The British Journal of Dermatology·O ServitjeJ Peyrí
Apr 13, 2000·The New England Journal of Medicine·G M FelkerE K Kasper
Apr 20, 2000·The Journal of Biological Chemistry·X SunD Kufe
Jun 10, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D SantiniG Di Sciascio
Oct 19, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T SafraA Gabizon
Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S GordonD Adelman
Apr 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G GrasselliL Gianni
May 2, 2002·Nature Medicine·Steven A CroneKuo-Fee Lee
Jun 20, 2002·Proceedings of the National Academy of Sciences of the United States of America·Cemil OzcelikAlistair N Garratt
Jun 22, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N FrickhofenM Sigmund
Aug 16, 2002·The New England Journal of Medicine·George D DemetriHeikki Joensuu
Sep 19, 2002·Cancer·Deborah L Keefe
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz KabbinavarEmily Bergsland
Mar 15, 2003·The New England Journal of Medicine·Stephen G O'BrienUNKNOWN IRIS Investigators
May 2, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Blanche Mavromatis, Bruce D Cheson
May 31, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B C KuenenH M Pinedo
Jun 13, 2003·The New England Journal of Medicine·Ian E Smith, Mitch Dowsett
Sep 23, 2003·Cardiovascular Toxicology·Brian B HasinoffErwin Huebner
Jan 21, 2004·Cardiovascular Research·Joerg HerrmannAmir Lerman
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzRobert J Mayer
Mar 5, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M E R O'BrienUNKNOWN CAELYX Breast Cancer Study Group
Mar 23, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Hélène FrançoisChristos Chatziantoniou
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Jun 5, 2004·The Breast : Official Journal of the European Society of Mastology·T M SuterC Barton
Jul 17, 2004·Science·Neil P ShahCharles L Sawyers
Jul 23, 2004·The New England Journal of Medicine·David CunninghamEric Van Cutsem
Jul 29, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P MarchettiC Ficorella

❮ Previous
Next ❯

Citations

Jul 31, 2013·Chinese Journal of Integrative Medicine·Hong-Yan TianZhao-Hua Dou
Sep 21, 2013·Cardiovascular Toxicology·Luciana Grazziotin RossatoFernando Remião
Oct 31, 2012·Genes & Nutrition·Ba Tiep NguyenHubertus Jarry
Dec 17, 2009·Journal of the National Cancer Institute·Adriana AlbiniDouglas M Noonan
Jan 14, 2009·Molecular Cancer Therapeutics·Nathan T Ihle, Garth Powis
Mar 13, 2012·Annual Review of Nutrition·William B Weglicki
Jan 22, 2010·Women's Health·Poornima BhupathyLeslie Anne Leinwand
Sep 29, 2011·Drug Metabolism Reviews·Veronika HanušováLenka Skálová
Aug 12, 2010·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·V HanusováL Skálová
Jun 8, 2013·Pharmacological Reports : PR·Veronika HanušováLenka Skálová
Mar 26, 2013·Critical Reviews in Oncology/hematology·Rossana BerardiStefano Cascinu
Nov 23, 2011·Blood Cells, Molecules & Diseases·Anjani KumarSukh Mahendra Singh
Jul 14, 2011·Heart Failure Clinics·Heloisa SawayaMarielle Scherrer-Crosbie
Aug 24, 2010·Progress in Cardiovascular Diseases·Douglas L Mann, Ronald J Krone
Jan 13, 2012·Veterinary and Comparative Oncology·A M MarringtonL Blackwood
Mar 1, 2012·Veterinary and Comparative Oncology·J W ElliottL Blackwood
Jan 6, 2012·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·V HanušováL Skálová
Apr 30, 2013·Neuromuscular Disorders : NMD·Daniele OrsucciGabriele Siciliano
Nov 19, 2013·Journal of Molecular and Cellular Cardiology·Dan L Li, Joseph A Hill
Sep 25, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Elizabeth L Strevel, Lillian L Siu
Dec 20, 2016·Revista da Associação Médica Brasileira·Élide Sbardellotto Mariano da Costa, Adriano Hyeda
Apr 9, 2010·Anti-cancer Drugs·Sandra GeigerHans-Joachim Stemmler
Sep 10, 2019·The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology·Hyang-Ae LeeKi-Suk Kim
Aug 2, 2017·Journal of Cardiovascular Pharmacology·Maradumane L MohanSathyamangla V Naga Prasad
Jan 30, 2021·Computational and Structural Biotechnology Journal·Eitan MargulisMasha Y Niv

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.